Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- Study 380-1878 evaluated the efficacy and safety of switching virologically suppressed adult patients with HIV from a multitablet regimen containing a boosted PI to fixed-dose bictegravir/emtricitabine/tenofovir AF[Daar 2018]
- Switch to bictegravir/emtricitabine/tenofovir AF was found to be noninferior to continuing a boosted PI–containing regimen and demonstrated no treatment-emergent resistance at 48 weeks
- In Study 380-1844 adults with HIV and estimated glomerular filtration rate ≥ 50 mL/min who were virologically suppressed on the coformulated regimen abacavir/dolutegravir/lamivudine or its separate components (dolutegravir + abacavir/lamivudine) were randomized 1:1 to switch to bictegravir/emtricitabine/tenofovir AF or to continue their current dolutegravir regimen[Molina 2018]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Switch Strategies